Great Lakes Advisors LLC Buys Shares of 8,588 DaVita Inc. $DVA

Great Lakes Advisors LLC bought a new position in DaVita Inc. (NYSE:DVA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,588 shares of the company’s stock, valued at approximately $1,911,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DVA. BlackRock Inc. bought a new stake in DaVita in the 2nd quarter worth about $547,520,000. Arrowstreet Capital Limited Partnership lifted its stake in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of DaVita during the 2nd quarter valued at about $101,127,000. Norges Bank bought a new stake in shares of DaVita in the fourth quarter worth approximately $49,164,000. Finally, Corient Private Wealth LLC grew its stake in shares of DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after acquiring an additional 335,809 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

NYSE:DVA opened at $174.21 on Friday. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49. The business has a fifty day moving average price of $214.96 and a 200-day moving average price of $181.53. The firm has a market capitalization of $11.11 billion, a price-to-earnings ratio of 14.26, a price-to-earnings-growth ratio of 0.58 and a beta of 0.88.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the previous year, the business earned $2.95 earnings per share. DaVita’s quarterly revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts expect that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DVA shares. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Oppenheimer set a $220.00 target price on shares of DaVita in a research note on Friday, August 7th. Barclays increased their price target on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Truist Financial reduced their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Finally, UBS Group increased their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $221.75.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.